MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative ...
MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRX) (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services ...
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRX) (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services ...
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has ...
CVRx , Inc. (NASDAQ:CVRX), a medical device company with a market capitalization of $382 million specializing in the development and commercialization of the Barostim therapy for heart failure and ...
CVRx Inc (NASDAQ:CVRX) announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of ...
MINNEAPOLIS - CVRx, Inc. (NASDAQ:CVRX) announced Tuesday that Category I Current Procedural Terminology (CPT) codes for its Barostim therapy have replaced the previous Category III codes, effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback